{"classes":[{"categories":[{"measurements":[{"comment":"Not calculable/estimable due to low number of participants with events","groupId":"OG000","lowerLimit":"11.0","upperLimit":"NA","value":"220.0"},{"comment":"Not calculable/estimable due to low number of participants with events","groupId":"OG001","lowerLimit":"57.0","upperLimit":"NA","value":"NA"},{"comment":"Not calculable/estimable due to low number of participants with events","groupId":"OG002","lowerLimit":"11.0","upperLimit":"NA","value":"320.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"8"}],"units":"Participants"}],"description":"PFS is defined as the number of days from the date of first dose of any study drug to the date of disease progression or death, whichever occurs first. All disease progression was to be included regardless of whether the event occurred during or after the participant was taking any study drug.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants positive for t(11;14) translocation who received at least 1 dose of study drug (venetoclax 400 mg, pomalidomide 4 mg, and dexamethasone 40 mg)","id":"OG000","title":"Participants Positive for t(11;14) Translocation"},{"description":"Participants negative for t(11;14) translocation who received at least 1 dose of study drug (venetoclax 400 mg, pomalidomide 4 mg, and dexamethasone 40 mg)","id":"OG001","title":"Participants Negative for t(11;14) Translocation"},{"description":"Participants who received at least 1 dose of study drug (venetoclax 400 mg, pomalidomide 4 mg, and dexamethasone 40 mg)","id":"OG002","title":"All Participants"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set: participants who received at least 1 dose of study drug (venetoclax 400 mg, pomalidomide 4 mg, and dexamethasone 40 mg)","reportingStatus":"POSTED","timeFrame":"Approximately 20 months","title":"Progression-Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"days"}